Toray Industries, Japan Tobacco, Torii Pharmaceutical to Collaborate
Toray Industries, Japan Tobacco and Torii Pharmaceutical jointly announced that they have entered into a contract for TRK-820, a selective kappa opioid receptor agonist. Developed by Toray's Pharmaceutical Research Laboratory, TRK-820 is a candidate for antipruritus drug for patients with hemodialysis. Under the terms of the agreement, Toray and Japan Tobacco will carry out further development and Torii Pharmaceutical will handle sales.
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9622)